CardieX Ltd lifts FY21 sales growth target on the back of strong March quarter
Sales since the beginning of 2021 have increased by more than 30% compared to the same period in fiscal year 20. () has raised its forecast for fiscal 2021 revenue growth after a successful March quarter by 40%. CardieX, a global medical technology company focused on hypertension, cardiovascular disease, and other vascular diseases, posted steady revenue growth in the penultimate quarter of fiscal 21. Excluding royalties, medical device sales increased 30% year over year on a currency-neutral basis, with key new team members and market growth driving the increased sales targets. Two pillar strategy CardieX CEO and General Manager Craig Cooper said the company is investing in both medical device products and wearable devices for consumers to diversify its product offerings and create value for shareholders. "Ultimately, under the CardieX Holding, we will have two separate but intertwined businesses," he said. “ATCOR will continue our traditional medical dev
